Cobalamins function as allosteric activators of an Angelman syndrome‐associated UBE3A/E6AP variant
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: ChemBioChem. Wiley. 2024, 25(10), e202400184. ISSN 1439-4227. eISSN 1439-7633. Verfügbar unter: doi: 10.1002/cbic.202400184
- Ereignis
-
Veröffentlichung
- (wo)
-
Konstanz
- (wer)
-
KOPS Universität Konstanz
- (wann)
-
2024
- Urheber
-
Müller, Franziska
Jansen, Jasmin
Offensperger, Fabian
Eichbichler, Daniela
Stengel, Florian
Scheffner, Martin
- URN
-
urn:nbn:de:bsz:352-2-10r6gjgw872611
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:39 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Müller, Franziska
- Jansen, Jasmin
- Offensperger, Fabian
- Eichbichler, Daniela
- Stengel, Florian
- Scheffner, Martin
- KOPS Universität Konstanz
Entstanden
- 2024
Ähnliche Objekte (12)
Cobalamins Function as Allosteric Activators of an Angelman Syndrome‐Associated UBE3A/E6AP Variant
Identification of Small-Molecule Activators of the Ubiquitin Ligase E6AP/UBE3A and Angelman Syndrome-Derived E6AP/UBE3A Variants
Outcome measures in Angelman syndrome
Gliflozins, sucrose and flavonoids are allosteric activators of lecithin-cholesterol acyltransferase
A web-based, patient driven registry for Angelman syndrome: the global Angelman syndrome registry
Epilepsy in patients with Angelman syndrome
Sleep disturbance in Angelman syndrome patients
On-target and off-target effects of novel orthosteric and allosteric activators of GPR84
Clinical, Molecular, and Neurophysiological Features in Angelman Syndrome
Cortical and subcortical morphological alteration in Angelman syndrome
Design, synthesis and evaluation of novel 3,5-disubstituted benzamide derivatives as allosteric glucokinase activators
An Overview of the Adaptive Behaviour Profile in Young Children with Angelman Syndrome: Insights from the Global Angelman Syndrome Registry
Cobalamins Function as Allosteric Activators of an Angelman Syndrome‐Associated UBE3A/E6AP Variant
Identification of Small-Molecule Activators of the Ubiquitin Ligase E6AP/UBE3A and Angelman Syndrome-Derived E6AP/UBE3A Variants
Outcome measures in Angelman syndrome
Gliflozins, sucrose and flavonoids are allosteric activators of lecithin-cholesterol acyltransferase
A web-based, patient driven registry for Angelman syndrome: the global Angelman syndrome registry
Epilepsy in patients with Angelman syndrome
Sleep disturbance in Angelman syndrome patients
On-target and off-target effects of novel orthosteric and allosteric activators of GPR84
Clinical, Molecular, and Neurophysiological Features in Angelman Syndrome
Cortical and subcortical morphological alteration in Angelman syndrome
Design, synthesis and evaluation of novel 3,5-disubstituted benzamide derivatives as allosteric glucokinase activators
An Overview of the Adaptive Behaviour Profile in Young Children with Angelman Syndrome: Insights from the Global Angelman Syndrome Registry
Cobalamins Function as Allosteric Activators of an Angelman Syndrome‐Associated UBE3A/E6AP Variant
Identification of Small-Molecule Activators of the Ubiquitin Ligase E6AP/UBE3A and Angelman Syndrome-Derived E6AP/UBE3A Variants
Outcome measures in Angelman syndrome
Gliflozins, sucrose and flavonoids are allosteric activators of lecithin-cholesterol acyltransferase
A web-based, patient driven registry for Angelman syndrome: the global Angelman syndrome registry
Epilepsy in patients with Angelman syndrome
Sleep disturbance in Angelman syndrome patients
On-target and off-target effects of novel orthosteric and allosteric activators of GPR84
Clinical, Molecular, and Neurophysiological Features in Angelman Syndrome
Cortical and subcortical morphological alteration in Angelman syndrome
Design, synthesis and evaluation of novel 3,5-disubstituted benzamide derivatives as allosteric glucokinase activators